How Much Did ViiMed Raise?
Funding & Key Investors

ViiMed has successfully secured a total capital infusion of $7M, marking a significant milestone in its corporate trajectory. The most recent financing round, which accounted for $5M, underscores the firm's robust position within the competitive healthcare technology landscape. This major strategic investment serves as a testament to the company's ability to attract substantial backing while scaling its enterprise-level operations to meet the evolving demands of modern medical care coordination.

What is ViiMed?

ViiMed
SoftwareHealthcare Software

ViiMed operates as a specialized healthcare technology provider, focusing on the development of sophisticated patient management and care coordination platforms. By integrating advanced digital solutions into clinical workflows, the company enables healthcare organizations to optimize operational efficiency and elevate patient outcomes. The firm's core value proposition lies in its commitment to transforming the traditional healthcare experience through technology-driven infrastructure. As the industry shifts toward value-based care, ViiMed provides the essential tools required for providers to streamline complex administrative and clinical processes, ensuring that care delivery remains both effective and scalable across diverse medical environments.

How much funding has ViiMed raised?

ViiMed has raised a total of $7M across 3 funding rounds:

2013

Series A

$1.4M

2014

Private Equity

$650K

2016

Private Equity

$5M

Series A (2013): $1.4M with participation from Wasabi Ventures

Private Equity (2014): $650K, investors not publicly disclosed

Private Equity (2016): $5M, investors not publicly disclosed

Key Investors in ViiMed

Wasabi Ventures

Wasabi Ventures Partners is a venture capital firm that provides accredited investors with access to early-stage startup opportunities through a rigorous triple-vetting process. The firm specializes in portfolio management and comprehensive due diligence to mitigate risk while identifying high-growth potential in the technology sector.

Undisclosed Investor

Undisclosed investor participating in the funding round.

Undisclosed Investor

Undisclosed investor participating in the funding round.

What's next for ViiMed?

With the recent influx of capital, ViiMed is well-positioned to accelerate its product development roadmap and expand its market footprint. The company is expected to leverage this financial backing to enhance its software-as-a-service capabilities, potentially targeting broader enterprise adoption among large-scale healthcare systems. Strategic priorities likely include the integration of predictive analytics and interoperability features to further differentiate its platform in a crowded market. By focusing on long-term sustainability and technological innovation, ViiMed aims to solidify its role as a critical partner for healthcare professionals navigating the complexities of digital transformation and patient-centric care models.

See full ViiMed company page
See More Financial Insights
No matching results.
Refine your search.

Additional financial insights in the Software industry

Content & Collaboration SoftwareSoftware
Content & Collaboration SoftwareSoftware
Healthcare SoftwareSoftware
Healthcare SoftwareSoftwareBusiness ServicesSoftware Testing

Frequently Asked Questions Regarding ViiMed Financial Insights

What are the most recent funding rounds that ViiMed has completed, and what were the funding rounds?
ViiMed has recently completed 3 funding rounds: Private Equity on Feb 3, 2016, Private Equity on Mar 26, 2014, Series A on Jun 3, 2013.
What is the total amount of funding ViiMed has raised to date?
ViiMed has raised a total of $7M in funding to date.
How many funding rounds has ViiMed completed?
ViiMed has completed 3 funding rounds.
How much funding did ViiMed raise in its most recent funding round?
ViiMed raised $5M in its most recent funding round.
Which was the largest funding round in ViiMed's history?
The largest funding round in ViiMed's history was $5M.
See more information about ViiMed